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Background:  Synthetic  hemozoin  (sHZ,  also known  as  -hematin)  from  monomeric  heme  is a  particle
adjuvant  which  activates  antigen-presenting  cells  (APCs),  such  as dendritic  cells  and  macrophages,  and
enhances  humoral  immune  responses  to several  antigens,  including  ovalbumin,  human  serum  albumin,
and  serine  repeat  antigen  36 of  Plasmodium  falciparum.  In  the  present  study,  we  evaluated  the adjuvan-
ticity  and pyrogenicity  of  sHZ  as an  adjuvant  for seasonal  trivalent  hemagglutinin  split  vaccine  (SV)  for
humans  using  the  experimental  ferret  model.
Method: Ferrets  were  twice  immunized  with  trivalent  SV,  SV with  sHZ  (SV/sHZ)  or Fluad,  composed  of
trivalent  SV with  MF59.  Serum  hemagglutination  inhibition  (HI)  titers  against  three  viral  hemagglutinin
(HA)  antigens  were  measured  at every  week  after  the immunization.  The  pyrogenicity  of  SV/sHZ  was
examined  by  monitoring  the  body  temperature  of the  immunized  ferrets.  To  evaluate  the  protective
efﬁcacy  of  SV/sHZ,  the  immunized  ferrets  were  challenged  with  inﬂuenza  virus  B  infection,  followed  by
measurement  of  viral  titers  in  the  nasal  cavity  and  body  temperature.
Results: sHZ  enhanced  HI titers  against  three  viral  HA  antigens  in  a dose-dependent  manner,  to  an  extent
comparable  to that  of  Fluad.  The  highest  dose  of  sHZ  (800  g) immunized  with  SV  conferred  sterile
protection  against  infection  with  heterologous  Inﬂuenza  B virus,  without  causing  any  pyrogenic  reaction
such  as high  fever.
Conclusion: In the  present  study,  sHZ  enhanced  the  protective  efﬁcacy  of  SV against  inﬂuenza  infection
without  inducing  pyrogenic  reaction,  suggesting  sHZ  to be a promising  adjuvant  candidate  for  human
SV.
Publi©  2014  The  Authors.  
. Introduction
Hemozoin (HZ) is a detoxiﬁcation product of heme molecules
ersisting in the food vacuoles of Plasmodium parasite [1,2]. Puri-
ed HZ activates innate immune responses via Toll-like receptor
TLR)9 in antigen-presenting cells (APCs), including myeloid and
lasmacytoid dendritic cells [3], and enhances humoral responses
epending TLR9 but not NACHT, LRR and PYD domains containing
Abbreviations: sHZ, synthetic hemozoin; HA, hemagglutinin; HI, hemagglutina-
ion  inhibition; SV, hemagglutinin split vaccine; SV/sHZ, hemagglutinin split vaccine
djuvanted with synthetic hemozoin; TCID50, 50% tissue culture infective dose.
∗ Corresponding author at: NIBIO, 7-6-8 Asagi, Saito, Ibaraki, Osaka 5670085,
apan.  Tel.: +81 72 641 8043; fax: +81 72 641 8079.
E-mail addresses: kenishii@biken.osaka-u.ac.jp, kenishii@nibio.go.jp (K.J. Ishii).
ttp://dx.doi.org/10.1016/j.vaccine.2014.03.072
264-410X/© 2014 The Authors. Published by Elsevier Ltd. This is an open access article unshed  by Elsevier  Ltd. This  is  an open  access  article  under  the  CC  BY-NC-SA
license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
the protein 3 (NALP3) inﬂammasome signaling pathway [4]. Syn-
thetic hemozoin (sHZ, also known as -hematin) from monomeric
heme also activates APCs, and enhances the humoral responses
of several antigens, including ovalbumin, human serum albumin,
and serine repeat antigen 36 of Plasmodium falciparum in mice
or cynomolgus monkeys (Macaca fascicularis) [4,5]. Moreover, sHZ
acts as a potent immune modulator, which suppresses IgE produc-
tion against house dust allergens, suggesting that sHZ itself might
be usable for an allergy vaccine for dogs [4]. Differently from the
puriﬁed HZ, sHZ enhance the adaptive immune response through
MyD88, not related to TLR9 or NALP3 inﬂammasome pathway [4].
Thus, the efﬁcacy, safety, and immunological mechanisms of sHZ
has been demonstrated, further studies are needed to explore its
application as an adjuvant for vaccines.
In general, the efﬁcacy of inﬂuenza hemagglutinin split vac-
cine (SV) correlates with the level of neutralizing antibody to
der the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
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emagglutinin (HA) [6]. The neutralizing antibody contributes to
oth prevention of inﬂuenza infection and suppression of inﬂuenza
xacerbation. Some reports have estimated the efﬁcacy of inﬂuenza
accine in young adults to be 70–90%, and that in the elderly to be
onsiderably lower, in the range of 17–53% [7]. Hence, SV is required
o improve the efﬁcacy for the elderly. One possible solution of
he issue is via the use of adjuvant [8], although some adjuvants
ave been reported to cause pyrogenic reaction associated with the
nduction of proinﬂammatory cytokine responses in clinical stud-
es [9,10]. Therefore, it is important to evaluate the pyrogenicity of
djuvant in clinical or non-clinical studies to enable wider use of
djuvants.
In the present study, we evaluated the efﬁcacy and pyrogenicity
f sHZ as an adjuvant for seasonal trivalent SV in the ferret model.
.  Materials and methods
.1.  Antigens and adjuvants
Seasonal  inﬂuenza SV “BIKEN”, containing inﬂuenza virus HA
urface antigens from three virus strains, A/California/7/2009
H1N1), A/Victoria/210/2009 (H3N2), and B/Brisbane/60/2008, was
btained from The Research Foundation for Microbial Diseases of
saka University (Osaka, Japan) [11]. Endotoxin-free sHZ chem-
cally synthesized using an acidic method was obtained from
nvivogen (San Diego, CA) [12]. The particle size of sHZ was  deter-
ined by SEM and found to be approximately 1–2 m.  Fluad,
omposed of inﬂuenza virus HA surface antigens from the three
trains described above and MF59, was obtained from Novartis
accines and Diagnostics, Inc. (Emeryville, CA) [13].
.2.  Virus and cells
Inﬂuenza  virus B/Osaka/32/2009 was kindly provided by Osaka
refectural Institute of Public Health. Madin–Darby canine kid-
ey (MDCK) cells were obtained from the American Type Culture
ollection (Manassas, VA) and were grown in minimum essential
edium (MEM;  Invitrogen, Carlsbad, CA) supplemented with 10%
etal bovine serum (Invitrogen) and 100 g/ml kanamycin sulfate
Invitrogen) in a humidiﬁed atmosphere of 5% CO2 at 37 ◦C.
.3.  Ferrets
Approximately 7- to 8-month-old female ferrets were pur-
hased from Marshall Bioresources Japan Inc. (Ibaragi, Japan)
nd Japan SLC Inc. (Shizuoka, Japan). The experiments were per-
ormed under applicable laws and guidelines and after approval
rom the Shionogi Animal Care and Use Committee. Under anes-
hesia, at least 1 week before virus inoculation, a data logger
DS1921H-F5; Maxim Integrated Products, Inc., Sunnyvale, CA) was
ubcutaneously implanted into each ferret to monitor body tem-
erature as previously reported [14]. The absence of inﬂuenza
/California/7/2009 (H1N1), A/Victoria/210/2009 (H3N2), and
/Brisbane/60/2008 virus-speciﬁc antibody in serum from each fer-
et was conﬁrmed by hemagglutination inhibition (HI) test before
he ﬁrst immunization.
.4.  HI assay
HI  assay was performed according to the protocol previously
eported [14]. Serum was treated with receptor-destroying enzyme
RDEII; Denka Seiken, Tokyo, Japan). Serially diluted sera were
ixed with 4 HA units of virus antigen for 1 h at room tempera-
ure. The mixture was then incubated with 0.5% chicken red blood
ells for 30 min  at room temperature. The HI titers were expressed (2014) 3004–3009 3005
as  reciprocals of the highest dilution of serum samples that com-
pletely inhibited hemagglutination.
2.5.  Immunization and sample collection
Ferrets were subcutaneously immunized with 22.5 g of
SV, 22.5 g of SV adjuvanted with 50–800 g of sHZ (SV/sHZ
(50–800 g)) or premix solution Fluad, which is composed of
22.5 g of SV and MF59. Second immunizations were conducted
28 days after the ﬁrst immunization. Serum was collected by
vena cava puncture on the day of the ﬁrst immunization and
7, 14, 21, 28, and 35 days after the ﬁrst immunization, and
HI titers against three HA antigens, A/California/7/2009 (H1N1),
A/Victoria/210/2009 (H3N2), and B/Brisbane/60/2008, were deter-
mined.
2.6. Evaluation of pyrogenicity of vaccine with adjuvant in ferrets
Ferrets were subcutaneously immunized with saline or 22.5 g
of SV adjuvanted with 800 g of sHZ. Body temperatures were mon-
itored every 15 min  with the data logger implanted in the ferrets.
2.7. Evaluation of protective effect of vaccine against inﬂuenza
virus  infection
Under anesthesia, ferrets were inoculated intranasally with
B/Osaka/32/2009 (1.0 × 104 TCID50) in 400 l of phosphate-
buffered saline (PBS). To monitor virus replication in nasal cavities,
nasal washes were collected from infected ferrets on days 1 to
6 after infection. The collected samples were stored at below
−80 ◦C until use. For virus titration, serial dilutions of nasal washes
were inoculated onto conﬂuent MDCK cells in 96-well plates.
After 1 h incubation, the suspension was  removed, and the cells
were cultured in MEM  including 0.5% bovine serum albumin (BSA;
Sigma-Aldrich) and 3 g/ml trypsin. The plates were incubated
at 37 ◦C in 5% CO2 for 3 days. The presence of cytopathic effects
(CPEs) was determined under a microscope, and viral titers were
calculated as log10 of TCID50/ml. When no CPE was observed using
undiluted viral solution, it was  deﬁned as an undetectable level,
which was  considered to be lower than 1.4 log10 of TCID50/ml.
2.8.  Activation of the inﬂammasome in peritoneal resident
macrophages
Activation of the inﬂammasome in peritoneal resident
macrophages was examined according to the protocol previously
reported [15]. Brieﬂy, peritoneal resident macrophages were col-
lected from C57BL/6 mice (Charles River Laboratories Japan, Inc.,
Kanagawa, Japan) and were prepared with complete RPMI1640
medium (Invitrogen). Macrophages were primed with 50 ng/ml LPS
(Sigma-Aldrich) for 18 h and then stimulated with sHZ or Alum
(Invivogen) for 8 h. The concentration of IL-1 in supernatant was
measured by ELISA (R&D systems, Minneapolis, MN).
2.9.  Statistical analysis
Viral  titers and body temperature of each animal were cal-
culated as the area under the curve (AUC) by the trapezoidal
method. Statistical signiﬁcance between groups was  determined
by Dunnett’s multiple comparison test using the statistical anal-
ysis software SAS (version 9.2) for Windows (SAS Institute, Cary,
NC).
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8,  and 35 after the ﬁrst immunization, and HI titers against three HA antigens of A
C) were measured. * p < 0.05 by Dunnett’s multiple comparison test vs. SV group (n
. Results
.1. sHZ enhanced immunogenicity of HA split vaccine in a
ose-dependent manner
To  examine the adjuvant effect of sHZ on HA split vaccine, ferrets
n = 4 per group) were twice immunized with SV with or without
HZ (800 g) or Fluad, and then their serum HI titers were mea-
ured every week. Fluad is composed of SV adjuvanted with MF59, a
icensed squalene-based emulsion, widely used in clinical settings
16]. On day 28 after the ﬁrst immunization, HI titers of SV/sHZ
roup against H1, H3, and B virus antigens were signiﬁcantly up-
egulated, of which the GMT  was 135, 28, and 40, respectively,
omparable to those elicited by MF59 (p < 0.05, Fig. 1A–C). After
he second immunization, HI titers of the SV/sHZ group against all
hree antigens were signiﬁcantly higher than those of the SV group
n day 35 (p < 0.05) (Fig. 1A–C). The GMTs of the HI titers against
1, H3, and B antigens in the SV/sHZ group were 905, 190, and
81, respectively. The boosting effect of sHZ was also comparable
o that of MF59. By contrast, HI titers against three HA antigens of
he SV group were not enhanced at every analysis point (Fig. 1A–C).
hese results demonstrated that sHZ has a potent adjuvanticity to
nhance the immunogenicity of SV, and its activity was comparable
o that of MF59 in ferrets.
Next,  the dose-dependent adjuvanticity of sHZ to enhance the
mmunogenicity of SV was examined. Ferrets were twice immu-
ized with SV/sHZ (50–800 g), and HI titers were measured at
very week. The adjuvanticity to enhance HI titers against HA anti-
ens of H1 and B was observed with at least 200 g of sHZ after
he ﬁrst immunization, but no boosting effect of 200 g of sHZ was
bserved after the second immunization (Fig. 2). Overall, each HI
iter against all three HA antigens of SV/sHZ (800 g) was 3–20
old higher than that of SV/sHZ (200 g) on day 7 after the second
mmunization. Thus, 800 g of sHZ showed higher adjuvanticityunized with SV, SV/sHZ (800 g) or Fluad. Serum were collected on day 0, 7, 14, 21,
ornia/7/2009(H1N1) (A), A/Victoria/210/2009 (H3N2) (B), and B/Brisbane/60/2008
r group). Data represent the GMT  ± 95% conﬁdence interval.
than  200 g of sHZ. This result implied that sHZ enhanced the
immunogenicity of SV in a dose-dependent manner in ferrets.
3.2.  HA split vaccine adjuvanted with sHZ did not cause
pyrogenic reaction after immunization
It is reported that the ferret model can evaluate not only the
efﬁcacy of vaccine but also the pyrogenicity of immunostimula-
tory agents like TLR ligands (e.g. TLR7/8 agonist R848) and virion
components, and non-pyrogenicity of SV [17,18] To evaluate the
pyrogenicity of sHZ after the ﬁrst immunization, ferrets were
immunized with saline or SV/sHZ (800 g), and the body tempera-
tures of ferrets were monitored continuously. The results showed
that sHZ did not enhance the body temperature after immunization,
and no difference was  observed in body temperature between the
SV/sHZ and the saline groups, suggesting that sHZ does not have
the potential to induce a pyrogenic reaction in ferrets (Fig. 3).
3.3.  sHZ enhanced the protective efﬁcacy of HA split vaccine
against inﬂuenza virus infection
Having observed such potent adjuvanticity without pyrogenic-
ity of sHZ in ferrets, we  next evaluated the contribution of
sHZ-adjuvanted SV vaccine to its protective efﬁcacy. On day 7 after
the second immunization, the ferrets were intranasally infected
with B/Osaka/32/2009, and viral titers in nasal cavities were mea-
sured daily after infection. On day 2 after infection, each viral titer of
two groups SV/sHZ (200 g) and SV/sHZ (800 g) was signiﬁcantly
lower than that of the SV group (p < 0.01 and <0.001, respectively)
(Fig. 4A). Each viral titer AUC of SV/sHZ (200 g and 800 g) groups
was signiﬁcantly lower than that of the SV group (p < 0.01) (Fig. 4C).
The body temperature changes of ferrets were monitored from
2 days before to 5 days after infection. Comparing the SV group with
the SV/sHZ group showed that the elevations of body temperature
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verage of body temperature during the 2 days before immunization.
ere suppressed in all SV/sHZ groups in a dose-dependent manner
Fig. 4B). Moreover, body temperature change AUCs of all SV/sHZ
roups were lower than that of the SV vaccine group (Fig. 4D).
.  Discussion
Vaccination is the primary strategy to prevent inﬂuenza infec-
ion [19]. The efﬁcacy of inﬂuenza vaccine in young and healthy
dults is estimated to be 70–90%, but that in the elderly is lower
t 17–53% [7]. Dose escalation of antigen has been examined to
nhance the efﬁcacy of vaccine for the elderly [20]. However, this
s not a realistic approach without improvement of the manufac-
uring plants or manufacturing systems. As an alternative strategy,
he use of adjuvant may  help overcome these issues by enhancingnization, and HI titers against three HA antigens of A/California/7/2009(H1N1) (A),
y Dunnett’s multiple comparison test vs. SV group. Data represent the GMT  ± 95%
the  immunogenicity of inﬂuenza vaccine. In the present study, sHZ
enhanced the immunogenicity of SV and consequently elevated
its protective efﬁcacy against virus infection in the ferret model,
which has been shown to reﬂect inﬂuenza symptoms and pro-
tective immune responses to inﬂuenza infection in humans [21].
In particular, SV/sHZ (800 g) strongly suppressed the viral titer
below the detection limit and did not cause pyrogenic reaction
after immunization. These results suggested sHZ to be a promising
adjuvant candidate for human SV.
Pyrogenicity is one of the main issues in the development of
novel adjuvants for vaccine even with good adjuvanticity. There-
fore, minimizing toxicity remains one of the major challenges in
adjuvant research [22]. Treanor et al. reported that VAX125, a
recombinant HA inﬂuenza-ﬂagellin fusion vaccine, showed high
immunogenicity in clinical study [23], but in some cases, febrile
symptoms were observed in the ﬁrst 24 h following vaccination.
It was  suggested that the pyrogenic reaction was associated with
systemic proinﬂammatory cytokine responses. sHZ  induces the
production of IL-1 by activating NALP3 inﬂammasome path-
way in macrophages [24,25]. However, in the present study, sHZ
did not cause pyrogenic reaction after the ﬁrst immunization.
To ﬁnd insights into why sHZ did not show pyrogenicity, the
activity of sHZ to induce the NALP3 inﬂammasome was exam-
ined, and the results revealed that a relatively high concentration
(≥300 g/ml) of sHZ was  required to induce IL-1 production in
macrophages (Supplemental Fig. 1). Dostert et al. also demon-
strated that 150 g/ml sHZ could induce inﬂammasome in bone
marrow-derived macrophages [25]. These results suggested that
the activation of NALP3-inﬂammasome caused by sHZ was  very
low and did not act as a trigger to cause a pyrogenic reaction in
ferrets.Rapid systemic distribution of adjuvant is also understood to
enhance the risk of causing a pyrogenic reaction. Sauder et al.
reported that R848, which is known as an imidazoquinoline com-
pound and TLR7/8 agonist, caused a pyrogenic reaction correlated
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Fig. 4. Evaluation of the protective efﬁcacy of SV/sHZ against virus infection. B/Osaka/32/2009 (1.0 × 104 TCID50) was intranasally infected to ferrets immunized with SV
(n  = 6) or SV/sHZ (50, 200 or 800 g) (n = 3). Nasal wash ﬂuids were collected on days 1–6 after infection, and viral titers were measured (A). Data represent the means. Viral
titer AUCs were calculated using the trapezoidal rule on the basis of means of the viral titers (TCID50/ml) on days 1 to 6 (C). Data represent the mean ± standard deviation.
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ith the induction of proinﬂammatory cytokine responses in
ealthy adults [10]. This strong response was caused by rapid sys-
emic distribution of R848 after administration [10]. 3M-052 is
 lipid-modiﬁed imidazoquinoline compound derived from R848,
earing a C18 lipid moiety, for sustained release and incorporation
nto a bilayer liposome [26]. 3M-052 incorporated into liposome
omposed of dioleoylphosphatidylcholine (3M-052/PC) was shown
o avoid the induction of systemic proinﬂammatory cytokine
esponses [26]. In addition, the adjuvanticity of 3M-052/PC was
igher than that of R848. Therefore, persistent immunostimula-
ion at the injected site with adjuvant is thought to contribute to
ts potent adjuvanticity [26]. sHZ, synthesized by an acidic method,
ormed insoluble particles approximately 1–2 m in size. On day 35
fter the ﬁrst immunization, a small amount of sHZ was observed
t the immunized site (data not shown), suggesting that the dis-
ribution of sHZ was not rapid or was very limited in ferrets.
hus, slow systemic distribution of sHZ might contribute to pre-
ent a pyrogenic reaction and maintain potent adjuvanticity after
mmunization. The size of particle adjuvant is considered to affect
he particulate-induced immune responses such as the efﬁcient
ctivation of dendritic cells or adjuvant uptake of macrophages
27]. The smaller particles (20–200 nm)  are usually uptaken by
ndocytosis via clathrin-coated vesicles, caveolae or their indepen-
ent receptors, and preferentially ingested by dendritic cells. The
arger size particles (0.5–5 m)  are uptaken by macropinocytosis,
hile particles greater than 0.5 m are predominantly taken up
y phagocytosis, and primarily ingested by macrophages [28]. The
rystal size of sHZ can be adjusted by the modiﬁcation of synthetic
ethod, and smaller size sHZ (diameter range; 50 nm–1 m,  peak
f the frequency distribution; 50–200 nm)  exhibits higher adjuvan-
icity than larger size sHZ (>5 m)  in mice when immunized with
valbumin antigen [4]. This size-dependent adjuvanticity of sHZom the average of body temperature changes during 1 day (B). Data represent the
 the basis of the means of the body temperature change on days 0 to 5 (D). Data
mparison test vs. SV group.
is considered as the result from the manner of uptake of APCs. In
this study, we demonstrated the potent adjuvanticity of sHZ, which
contains approximately 1–2 m particles.
In the present study, we demonstrated that sHZ could enhance
the protective efﬁcacy of SV against inﬂuenza virus in ferrets with-
out causing a pyrogenic reaction. The ﬁndings of this study indicate
that sHZ is safe and has great potential for use as an adjuvant for
human SV.
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